Dataset Information


Comparative Efficacy of JAK Inhibitors for Moderate-To-Severe Rheumatoid Arthritis: A Network Meta-Analysis.

ABSTRACT: INTRODUCTION:Janus kinase (JAK) inhibitors are a class of targeted therapies for rheumatoid arthritis (RA) with established clinical efficacy. However, little is known about their efficacy compared with each other. This network meta-analysis (NMA) estimated the comparative efficacy of JAK inhibitors currently approved for RA. METHODS:A targeted literature review was conducted for phase III randomized controlled trials (RCTs) evaluating the efficacy of three approved JAK inhibitors (tofacitinib, baricitinib, and upadacitinib) as monotherapy or combination therapy among patients with moderate-to-severe RA who had inadequate response to conventional synthetic disease-modifying antirheumatic drugs (csDMARD-IR). Using Bayesian NMA, American College of Rheumatology (ACR) 20/50/70 responses and clinical remission (defined as DAS28-CRP?


PROVIDER: S-EPMC7467453 | BioStudies | 2020-01-01

REPOSITORIES: biostudies

Similar Datasets

2020-01-01 | S-EPMC7296727 | BioStudies
2019-01-01 | S-EPMC6857076 | BioStudies
2018-01-01 | S-EPMC6390583 | BioStudies
2019-01-01 | S-EPMC6679539 | BioStudies
2020-01-01 | S-EPMC7081656 | BioStudies
2019-01-01 | S-EPMC6876279 | BioStudies
2020-01-01 | S-EPMC7500842 | BioStudies
2019-01-01 | S-EPMC6343466 | BioStudies
2018-01-01 | S-EPMC5935623 | BioStudies
2020-01-01 | S-EPMC7408575 | BioStudies